See my earlier posts on IRA value negotiation on drug choice (Half 1) and producer information…
Tag: Economist
Half 1 – Healthcare Economist
CMS launched steerage on IRA worth negotiation final week. Beneath are some highlights relating to how…
Threat Adjustment and Incentives for Upcoding in Medicare – Healthcare Economist
To account for variations in illness burden throughout a Medicare Benefit (MA) plans affected person inhabitants,…
Do sufferers worth enhancements in progression-free survival? – Healthcare Economist
Development-free survival (PFS) is a surrogate endpoint is outlined as follows (by ChatGPT): In essence, PFS…
What would occur if we eradicated medical debt? – Healthcare Economist
Medical debt within the U.S. is a serious drawback. Whereas over…
Biosimilar Market Report – Healthcare Economist
Samsung Bioepis has a Biosimilar Market Report for Q2 2024. Some…
EMA and delays in drug launch – Healthcare Economist
For sufferers with critical sicknesses, timeline entry to efficacious medicines is paramount. The European Medicines Company…
An summary – Healthcare Economist
A paper by Kogut (2024) has a pleasant overview of the organizations that develop pharmacy plan…
Concerns in payer protection of digital therapeutics – Healthcare Economist
The Digital Therapeutics Alliance defines a digital therapeutic (DTx) as “evidence-based…
Why don’t physicians settle for Medicaid sufferers? – Healthcare Economist
One motive is that reimbursement charges for Medicaid are decrease than…